Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)

INTRODUCTION: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Acar, Mustafa, Juneja, Prabhjot, Handel, Malcolm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267492/
https://www.ncbi.nlm.nih.gov/pubmed/30568519
http://dx.doi.org/10.2147/OARRR.S179704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267492/
https://www.ncbi.nlm.nih.gov/pubmed/30568519
http://dx.doi.org/10.2147/OARRR.S179704

Ejemplares similares